Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Regul Toxicol Pharmacol ; 74: 117-22, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26619782

RESUMEN

The aim of this study was to evaluate the embryo-fetal development toxicity of honokiol microemulsion. The drug was intravenously injected to pregnant SD rats at dose levels of 0, 200, 600 and 2000 µg/kg/day from day 6-15 of gestation. All the pregnant animals were observed for body weights and any abnormal changes and subjected to caesarean-section on gestation day (GD) 20; all fetuses obtained from caesarean-section were assessed by external inspection, visceral and skeletal examinations. No treatment-related external alterations as well as visceral and skeletal malformations were observed in honokiol microemulsion groups. There was no significant difference in the body weight gain of the pregnant rats, average number of corpora lutea, and the gravid uterus weight in the honokiol microemulsion groups compared with the vehicle control group. However, at a dose level of 2000 µg/kg/day, there was embryo-fetal developmental toxicity observed, including a decrease in the body length and tail length of fetuses. In conclusion, the no-observed-adverse-effect level (NOAEL) of honokiol microemulsion is 600 µg/kg/day, 75 times above the therapeutic dosage and it has embryo-fetal toxicity at a dose level of 2000 µg/kg/day, which is approximately 250 times above the therapeutic dosage.


Asunto(s)
Compuestos de Bifenilo/toxicidad , Embrión de Mamíferos/efectos de los fármacos , Feto/efectos de los fármacos , Lignanos/toxicidad , Fármacos Neuroprotectores/toxicidad , Animales , Compuestos de Bifenilo/administración & dosificación , Relación Dosis-Respuesta a Droga , Embrión de Mamíferos/patología , Emulsiones , Femenino , Feto/patología , Edad Gestacional , Inyecciones Intravenosas , Lignanos/administración & dosificación , Exposición Materna , Fármacos Neuroprotectores/administración & dosificación , Nivel sin Efectos Adversos Observados , Embarazo , Ratas Sprague-Dawley , Medición de Riesgo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda